The umbilical cord (UC) matrix is a source of multipotent mesenchymal stem cells (MSCs) that have adipogenic potential and thus can be a model to study adipogenesis. However, existing variability in adipocytic differentiation outcomes may be due to discrepancies in methods utilized for adipogenic differentiation. Additionally, functional characterization of UCMSCs as adipocytes has not been described. We tested the potential of three well-established adipogenic cocktails containing IBMX, dexamethasone, and insulin (MDI) plus indomethacin (MDI-I) or rosiglitazone (MDI-R) to stimulate adipocyte differentiation in UCMSCs. MDI, MDI-I, and MDI-R treatment significantly increased peroxisome proliferator-activated receptor gamma (PPAR) and CCAATenhancer binding protein alpha (C/EBP) mRNA and induced lipid droplet formation. However, MDI-I had the greatest impact on mRNA expression of PPAR, C/EBP, FABP4, GPD1, PLIN1, PLIN2, and ADIPOQ and lipid accumulation, whereas MDI showed the least. Interestingly, there were no treatment group differences in the amount of PPAR protein. However, MDI-I treated cells had significantly more C/EBP protein compared to MDI or MDI-R, suggesting that indomethacin-dependent increased C/EBP may contribute to the adipogenesis-inducing potency of MDI-I. Additionally, bone morphogenetic protein 4 (BMP4) treatment of UCMSCs did not enhance responsiveness to MDI-induced differentiation. Finally to characterize adipocyte function, differentiated UCMSCs were stimulated with insulin and downstream signaling was assessed. Differentiated UCMSCs were responsive to insulin at two weeks but showed decreased sensitivity by five weeks following differentiation, suggesting that long-term differentiation may induce insulin resistance. Together, these data indicate that UCMSCs undergo adipogenesis when differentiated in MDI, MDI-I, and MDI-R, however the presence of indomethacin greatly enhances their adipogenic potential beyond that of rosiglitazone. Furthermore, our results suggest that insulin signaling pathways of differentiated UCMSCs are functionally similar to adipocytes.
Introduction
The umbilical cord (UC) matrix, also known as Wharton's Jelly, is a potential source of mesenchymal stem cells (MSCs) for clinical and therapeutic applications. 1,2 UC matrix cells have been characterized to have cell-surface markers typical of MSCs (positive for CD10, CD13, CD29, CD44, CD73, CD90, and CD105 and negative for CD14, CD33, CD56, CD31, CD34, and CD45) [3] [4] [5] and can differentiate into a number of cell types including: dermal fibroblasts, 6 osteoblasts, 7,8 chondrocytes, 7, 9 adipocytes, 7 myocytes, 10 hepatocytes, 11, 12 and neural cells. 13, 14 Furthermore, compared to embryonic stem cells, UCMSCs are a non-controversial resource of multipotent stem cells that can be obtained in large quantities, 4, 11 and have been shown to retain stem-like qualities over long-term culture. 15 In addition to their importance in tissue engineering, transplanted UCMSCs have recently been shown to provide therapeutic benefits in injured renal 16 and hepatic 17 tissue through the release of exosomes. UCMSCs also provide an easily accessible source of human stem cells that can be utilized to study the mechanisms regulating lineage differentiation. Finally, UCMSCs are likely to provide a unique resource to study the impact of developmental programming in the offspring.
The process of cellular differentiation into adipocytes (viz. adipogenesis) has been extensively studied due to the central role of adipose tissue in disorders such as obesity, type 2 diabetes, and numerous other related metabolic disorders. Obesity develops from a chronic positive energy imbalance, where energy intake exceeds energy expenditure. Throughout development, adipose tissue expansion is regulated by processes of hypertrophy and hyperplasia. Extensive hypertrophy, as often seen with obesity, can induce a metabolically inflexible and hormone-resistant state, driving the metabolic perturbations that accompany obesity. 18, 19 On the other hand, adipose tissue hyperplasia has been shown to help maintain a healthy and metabolically responsive phenotype. 19 The production of new adipocytes through adipogenesis proceeds through a series of finely tuned steps, beginning with commitment of cells to the adipocyte lineage and culminating in terminal differentiation and acquisition of adipocytic phenotype characterized by lipid accumulation. 20, 21 To date, many of the mechanisms regulating adipocyte function and differentiation have been widely examined using the mouse fibroblast-derived preadipocyte cell line, 3T3-L1. [22] [23] [24] Other studies have been carried out using bipotential or multipotential cell lines and primary mesenchymal cells isolated from the bone-marrow. UCMSCs also provide a relatively accessible human in vitro system to study adipogenesis and as a source of fetal stem cells, can be used to test the effects of the in utero environment on differentiation potential. Several differentiation protocols have been utilized to induce adipogenesis in UCMSCs (reviewed by Scott et al. 25 ), which can result in various phenotypic outcomes and levels of differentiation, indicating a need for studies that compare the outcomes of various differentiation protocols. Most importantly, characterization of the functionality of adipocytes differentiated from UCMSCs has not yet been described. Finally, although markers of terminal adipocyte differentiation have been characterized to some degree in these cells, 7,26-29 adipocyte commitment has not been explored.
In vitro differentiation of UCMSCs into adipocytes can be achieved by inducing adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPAR) and CCAAT-enhancer binding proteins (C/EBP and b), 30 with a differentiation cocktail termed MDI. MDI consists of a phosphodiesterase inhibitor (M: 3-isobutyl-1-methylxanthine, IBMX), a glucocorticoid (D: dexamethasone), and insulin (I). In most cases, MDI is supplemented with a cyclooxygenase inhibitor such as indomethacin or a PPAR agonist like rosiglitazone. Both indomethacin and rosiglitazone have been shown to induce adipogenesis through the stimulation of PPAR. [31] [32] [33] via slightly different mechanisms. Indomethacin drives PPAR expression, whereas rosiglitazone, a potent PPAR ligand, increases its transcriptional activity. 31 Furthermore, both chemicals have been shown to induce gene expression changes that are independent of PPAR activation 31, 34 that may lead to different levels of differentiation.
There were three main goals in this study to further characterize the adipogenic phenotype of UCMSCs. The first objective was to determine the adipogenic response of UCMSCs to three differentiation conditions: MDI, MDIindomethacin (MDI-I), and MDI-rosiglitazone (MDI-R) via analysis of cellular morphology, gene expression, and protein levels. Secondly, we set out to determine if treatment with bone morphogenetic protein 4 (BMP4), a potent inducer of adipocyte commitment in the murine mesenchymal stem cell line C3H10T1/2, 35 will commit UCMSCs to an adipocyte lineage, thereby enhancing the differentiation response to MDI, MDI-I, and/or MDI-R. Finally, we aimed to functionally characterize UCMSCs differentiated into adipocytes by testing their responsiveness to insulin challenge. We hypothesized that MDI-I will induce the greatest adipogenic response in UCMSCs, and that exposure to BMP4 will commit all cells to an adipocyte lineage, therefore eliminating the differential effects of the three types of differentiation media.
Materials and methods

Isolation of UCMSCs
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. UCs were collected at the University of Arkansas for Medical Sciences (UAMS), after obtaining written informed consent from mothers during the first trimester of pregnancy. The protocol was approved by the Institutional Review Board at the University of Arkansas for Medical Sciences (NCT01131117). Three inch pieces of UCs from two patients were washed three times with phosphate-buffered saline (PBS) containing 1% antibiotic-antimycotic (ABAM) (Life Technologies, Carlsbad, CA) and stored at 4 C until processing (within 2-3 h of collection). Cells from the UC matrix (UCMSCs) were isolated from the two UCs, pooled, and expanded using media as described elsewhere. 36 In brief, UCs were divided into 1 in pieces, sliced open longitudinally using a sterile surgical blade to expose the UC matrix, vessels were removed, and tissue was scored horizontally many times to help liberate the cells. Next, the tissue underwent a series of enzymatic digestions (300 U/mL collagenase þ 1 mg/mL hyaluronidase [45 min], and 0.25% trypsin-ethylene diamine tetraacetic acid [EDTA] [15 min]), followed by 10 min of scraping the tissue with forceps in 1 x PBS to remove cells. The solution was placed on a 100 mm cell strainer; cells were collected, and centrifuged at 1000 r/min for 5 min. UCMSCs were counted and plated in growth media (Supplemental Table  1 ) in a single well of a six-well plate. Cells were expanded until the third passage after which they were fluorescently labeled with antibodies against CD13, CD29, CD44, CD90, CD105, CD31, CD34, and CD45 (BioLegend, San Diego, CA) and analyzed via FACS. UCMSCs were then plated for adipogenesis experiments described below.
Cell culture and adipocyte differentiation
UCMSCs were maintained in growth media until reaching 80% confluence. Cells were plated for experimentation at 1 x 10 4 cells/cm 2 , one day prior to treatment with BMP4 (R&D Systems, Minneapolis, MN) or vehicle, after which media containing BMP4 (50, 100, 150 ng/mL) or vehicle, which was replaced every other day for four days. UCMSCs were either collected at this point or treated with adipogenic media: Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 1% ABAM, 1 mmol/L dexamethasone, 500 mmol/L IBMX, 1 mmol/L insulin (MDI) with the addition of either 60 mmol/L indomethacin (MDI-I), or 10 mmol/L rosiglitazone (Cayman Chemicals, Boston, MA) (MDI-R). Cells were cultured for up to five weeks with the appropriate adipogenic media replaced every third day. An insulin challenge was performed in some cases on differentiated cells. For these experiments, cells were serum starved for 16 h followed by treatment with 100 nmol/L insulin for 10 min. The insulin was removed, cells washed with PBS, and collected for protein analysis as described below.
mRNA isolation and qRT-PCR
Total RNA was isolated using a RNeasy Mini kit including on-column DNase digestion (Qiagen, Valencia, CA) from n ¼ 6 replicates per treatment group. RNA integrity was assessed using Experion RNA StdSens analysis kit (BioRad). Total RNA (1 mg) was reverse transcribed using iScript cDNA synthesis kit (BioRad), and subsequent realtime PCR analysis was performed using an ABI Prism 7500 FAST sequence detection system (Applied Biosystems, Foster City, CA). Gene specific primers were designed using Primer Express Software (Applied Biosystems). The relative amounts of mRNA were quantified using a standard curve and normalized to the expression of SRP14 mRNA. Primer sequences are depicted in Supplemental Table 2 . To confirm that the changes observed following adipogenic differentiation were not unique to the initial UCMSC samples, additional UCMSCs were collected from four more subjects, expanded individually and differentiated as mentioned above. At 0, 2, and 5 weeks after adipogenic differentiation, total RNA was isolated, reverse transcribed and used for real-time PCR analysis as described above.
Oil-red-O staining and microscopy
UCMSCs (n ¼ 3 replicates per treatment group) were fixed for 15 min in 3% paraformaldehyde, permeabilized with 0.1% Triton X-100 for 5 min, and blocked with PBS containing 5% BSA for 30 min at room temperature. To visualize lipid accumulation over the differentiation time course, cells were stained with a lipid soluble dye (Oil-red-O in 60% isopropanol) for 45 min, followed by three washes with PBS. Actin filaments were stained using Alexa fluor-488 phalloidin (Life Technologies) per manufacturer's instructions. All fluorescent labeling dyes were examined using an Axio Vert 200 fluorescent microscope (Carl Zeiss, Oberkochen, Germany). Axiovision software (Carl Zeiss) was used to semi-quantitatively estimate the amount of triglyceride (TG) storage by measuring the percentage of Oilred-O staining per 40 x field and normalizing to nuclear content (count of 4',6-diamidino-2-phenylindole [DAPI]stained nuclei/field). Lipid droplet size was also semiquantitatively estimated using Axiovision software, by dividing the total area stained with Oil-red-O in each field by the number of individual particles. Four 40 x fields were analyzed per sample (n ¼ 3 replicates per treatment group).
Protein isolation and immunoblotting
Total cell lysates from n ¼ 3-5 replicates per treatment group were prepared in RIPA buffer (25 mmol/L Tris-HCl, 150 mmol/L NaCl, 1.0% NP-40, 1.0% deoxycholic acid, 0.1% sodium dodecyl sulfate [SDS], 2 mmol/L EDTA) containing 1 mmol/L phenylmethanesulfonyl fluoride (PMSF) and protease inhibitor cocktail. Proteins were resolved by SDSpolyacrylamide gel electrophoresis (PAGE) and immunoblotting was carried out using standard procedures. 37 Membranes were incubated with primary antibodies against PPAR (#sc-7196), phosphorylated ERK1/2 (P-ERK1/2) (#sc-81492) (both from Santa Cruz Biotechnology Inc., Dallas, TX), C/EBP (#3087), C/EBPb (#229 C), AKT (#9272), phosphorylated AKT (P-AKT) (#5106S), JNK (#9258), phosphorylated JNK (P-JNK) (#4668), ERK1/2 (#46955), and -tubulin (#9099S) (Cell Signaling, Danvers, MA) for 16 h at 4 C. horseradish peroxidase (HRP)-conjugated secondary antibodies against rabbit and mouse IgG (Santa Cruz Biotechnology, Inc.) were used for protein detection. Quantitation of immunoblots was performed using Quantity One software (Biorad).
Statistical analysis
Real-time RT-PCR data are expressed as mean fold change from control AE SEM and all other data are expressed as means AE SEM. None of the data is transformed. Repeated measures two-way ANOVA followed by Tukey's or Sidak's multiple comparisons test was used to compare the three differentiation treatments across multiple time points. For BMP stimulation of UCMSCs, one-way ANOVA followed by all-pair wise comparison with the Student-Neuman-Keuls method was performed. For all statistical tests, P 0.05 was considered to be statistically significant. Statistical analyses were performed using GraphPad Prism 6 (v 6.02, La Jolla, CA).
Results
UC matrix cells express MSC surface markers
Flow cytometric analysis of cell surface antigens revealed that expanded UC cells homogenously expressed CD13, CD29, CD44, CD90, and CD105, whereas only 0.3% of cells expressed CD31, CD34, and CD45 (Figure 1 ), confirming a MSC phenotype.
MDI-I induces the greatest adipogenic response by five weeks
Adipocyte differentiation is characterized by the establishment of a transcriptional program that drives adipocytespecific gene expression and function. Consistent with adipocyte differentiation, MDI, MDI-I, and MDI-R treatment led to $six-fold and $five-fold increase in the expression of adipogenic transcriptional regulators, PPAR and C/EBP, respectively, by one week of treatment (P < 0.001, Figure 2a ). Additionally, mRNA expression of lipid droplet proteins, PLIN1 and PLIN2, were significantly induced (P < 0.001) by 5-fold and 4-fold with MDI, 38-fold and 14fold with MDI-I, and 105-fold and 12-fold MDI-R, respectively, following one week of differentiation (Figure 2a ).
Repeated measures two-way ANOVA indicated significant differences (P < 0.05) in the gene expression of PPAR, C/EBP, FABP4, GPD1, PLIN1, PLIN2, and ADIPOQ between groups at every time point following two weeks of differentiation (Figure 2a ). For all genes, MDI-I and MDI-R induced significantly greater gene expression than did treatment with MDI alone (P < 0.05). By five weeks, gene expression in cells differentiated with MDI-I was significantly greater than in cells differentiated with MDI or MDI-R for all genes (P < 0.001), with the exception of leptin where MDI-R induced the greatest expression ( Figure 2a ). Interestingly, UCMSCs differentiated in MDI-R had significantly greater mRNA expression of FABP4 (P < 0.001) and PLIN1 (P < 0.001) compared to MDI and MDI-I at two weeks of differentiation. Thereafter, a decrease or leveling off in gene expression for many of the adipogenic genes occurred in the MDI-R group.
To confirm that the changes in mRNA expression of adipogenic genes with varying differentiation conditions were not unique to the initial UCMSC samples, additional UCMSCs were isolated (N ¼ 4) and differentiated as described earlier. Total RNA was isolated at 0, 2, and 5 weeks after adipogenic differentiation and real-time PCR analysis of adipogenic differentiation genes was performed ( Figure 2b ). Similar to the results from initial time course studies, experiments with biological replicates also showed that at five weeks following differentiation, cells treated with MDI-I showed greater extent of differentiation as seen by enhanced expression of PPAR, C/EBP, GPD1, and PLIN1 compared to those differentiated with MDI or MDI-R.
TG accumulation in lipid droplets is indicative of a mature adipocyte and increases throughout the differentiation process. Therefore, the amount of TG present is a common way of measuring the degree of adipocyte differentiation. To measure TG accumulation, we performed semi-quantitative analysis of Oil-red-O stained UCMSCs differentiated in MDI, MDI-I, or MDI-R. Consistent with gene expression changes, lipid staining was apparent in nearly all cells treated with MDI, MDI-I, and MDI-R by one week (Figure 3a ) and progressively increased over the five weeks in both MDI and MDI-I treated cells (Figure 3b ). Similar to what was observed with gene expression, cells treated with MDI-R had a drop in lipid staining between two weeks and three weeks, after which TG storage increased to similar levels as those observed at one week post treatment, suggesting a potential loss of differentiation or differentiated cells. Repeated measures two-way ANOVA showed that after three weeks of treatment, cells differentiated in MDI-I had significantly more TG compared to either MDI or MDI-R. As differentiation progresses, adipocytes not only accumulate greater amounts of TG, but they also display larger lipid droplets. To semiquantitatively measure lipid droplet size, we divided the total area of Oil-red-O staining by the number of particles measured. Interestingly at two weeks, cells differentiated in MDI-R had significantly larger lipid droplets compared to MDI and MDI-I (Figure 3c ), which dramatically decreased by three weeks and was no longer different than MDI or MDI-I. By five weeks of differentiation, MDI-I had both more TG accumulation ( Figure 3b ) and significantly larger lipid droplets (Figure 3c ) than both MDI and MDI-R, suggesting that MDI-I had the most potent effect on adipocyte differentiation.
MDI-I drives adipogenesis by increasing C/EBPa
Next we measured protein levels of PPAR and C/EBP to ascertain if protein level changes paralleled the observed gene expression changes (Figure 4a ). Following two and five weeks of differentiation, PPAR protein levels were significantly increased by at least 1.5-fold and 2.5-fold, respectively (Figure 4b ), in all groups when compared to undifferentiated UCMSCs. However, in contrast to gene expression changes, there were no significant differences in PPAR protein levels between MDI, MDI-I, or MDI-R groups after five weeks of differentiation (Figure 4b ). On the other hand, C/EBP protein levels were more consistent with the observed gene expression changes (Figure 4a, c) . Accordingly, MDI-I treatment induced the greatest increase in C/EBP protein expression by two and five weeks (Figure 4c ). These data suggest that indomethacin may drive the expression of C/EBP independently of other adipogenic stimuli. C/EBP plays a significant role in regulating the genetic program that synchronizes adipogenesis and may therefore be the underlying mechanism for which MDI-I has such potent effects on adipocyte differentiation. To test if indomethacin could directly induce C/EBP levels, we cultured UCMSCs for 0, 1, and 3 days in DMEM supplemented with 10% FBS and 60 mmol/L indomethacin and measured protein levels of C/EBP and its upstream regulator C/EBPb ( Figure 5 ). Following one day of indomethacin treatment, we observed a 1.8-fold increase in the amount of C/EBPb protein but no increase in C/EBP. By three days of treatment there was a significant increase in both C/EBPb (2-fold) and C/EBP (1.5-fold) compared to untreated UCMSCs indicating that indomethacin can induce C/EBP protein in absence of MDI, most likely through stimulation of C/EBPb expression.
Commitment with BMP4 stimulation
Because UCMSCs treated with MDI showed the least amount of differentiation, we next tested the hypothesis that akin to the mouse clonal MSC cell line C3H10T1/2, commitment to an adipocyte lineage via BMP4 stimulation (a known regulator of adipocyte commitment 35 ) would increase the response of UCMSCs to MDI-induced differentiation ( Figure 6 ). Treatment with 50, 100, or 150 ng/mL of BMP4 for four days significantly increased mRNA expression of ZFP423 and decreased expression of WISP2 (Wnt1 signaling pathway protein) in UCMSCs, however, there was Repeated measures two-way ANOVA followed by Tukey's multiple comparison test was performed to compare treatment groups. For each time point, * represents a significant difference from MDI, y represents a significant difference between MDI-I and MDI-R, z represents a significant difference between MDI and MDI-R, and § represents a significant difference between MDI and MDI-I (P < 0.05). UCMSCs: umbilical cord mesenchymal stem cells no dose-dependent response to BMP4 treatment (Figure 6a ). Pre-treatment with 100 ng/mL of BMP4 showed a trend for increased TG storage in UCMSCs differentiated in MDI by one week, however there was no effect on UCMSCs differentiated in MDI-I or MDI-R (Figure 6b, c) . By five weeks of differentiation, there was no effect of BMP4 treatment on TG storage for any of the groups (Figure 6c ).
In cells pre-treated with BMP4 and differentiated for one week in MDI, there was no induction of PPAR, C/EBP, or FABP4 mRNA expression ( Figure 6d ). BMP4 pre-treated cells differentiated in MDI-I for one week also had no induction of PPAR, C/EBP, or FABP4 mRNA expression compared to control (Figure 6d ). By five weeks of differentiation, BMP4-treated cells differentiated in MDI-R showed significantly reduced expressions of PPAR and FABP4 compared to CON. BMP4 treatment led to significantly greater PPAR, C/EBP, and FABP4 gene expression by five weeks of differentiation in MDI-I compared to CON (Figure 6d ).
Differentiated UCMSCs are insulin responsive at two weeks and resistant by five weeks
To test if differentiated UCMSCs were insulin responsive, we stimulated cells with 100 nmol/L insulin or vehicle at two or five weeks post differentiation and measured total and phosphorylated protein levels of AKT, ERK1/2, and JNK (Figure 7a ). Following two weeks of differentiation, insulin stimulated a significant increase in ratio of phosphorylated AKT (P-AKT) to total AKT in cells treated with MDI, MDI-I, and MDI-R (Figure 7b ), suggesting that these cells were insulin sensitive. Cells differentiated in MDI-I had a five-fold induction of P-AKT to AKT, compared to a 2-fold or a 1.7-fold increase in MDI or MDI-R treated cells, respectively, in response to the insulin challenge, suggesting that UCMSCs differentiated in MDI-I are the most insulin responsive. By five weeks of differentiation, only the cells treated with MDI had a significantly increased P-AKT/AKT ratio (Figure 7b ) in response to insulin, suggesting that long-term exposure to MDI-I and MDI-R may induce insulin resistance in UCMSCs.
Mitogen-activated protein kinases (MAPKs), ERK1/2 and JNK are also insulin responsive and become phosphorylated following insulin stimulation. 38, 39 Interestingly, the ratio of P-ERK1/2 to ERK1/2 was not significantly increased in response to insulin for any of the time points or groups, suggesting that ERK1/2 signaling is not insulin responsive in UCMSCs (Figure 7c) . Insulin significantly increased the ratio of P-JNK to JNK in cells differentiated for two weeks in MDI and MDI-R by $1.7-fold (Figure 7d ). However, by five weeks of differentiation, insulin stimulation lead to a significant decrease in JNK activation in the MDI and MDI-R groups. Interestingly, there was no effect of insulin on JNK activation in cells differentiated with MDI-I at either two or five weeks (Figure 7d ).
Discussion
A number of cell culture models have been used to study the mechanisms regulating adipocyte differentiation. The UC is a recently identified source of MSCs that have adipogenic potential. 7, [26] [27] [28] 40, 41 As a novel source of fetal cells, UCMSCs can be used to determine if the in utero environment affects the differentiation potential of fetal stem cells. However, discrepancies exist regarding the techniques used to study in vitro adipogenic differentiation of these cells. 25, 42 Furthermore, their functional characterization as adipocytes and cellular commitment to the adipocyte lineage has not been described. In this study, we tested the potential of three adipogenic cocktails used to stimulate adipocyte differentiation in UCMSCs and found that all three induced adipocyte differentiation, albeit to different levels. MDI-I was the most effective in inducing adipocyte differentiation and our data suggest that indomethacindependent regulation of C/EBPb and C/EBP may be an underlying mechanism for the potent effects of MDI-I on UCMSC adipogenesis. Additionally, the present findings suggest that UCMSCs show minimal adipocyte differentiation in the absence of a PPAR ligand (MDI-treated), which cannot be rescued by BMP4-induced commitment. Finally, to our knowledge, we are the first to show that differentiated UCMSCs are insulin responsive early in differentiation but have decreased insulin sensitivity by five weeks of differentiation.
Cellular commitment to an adipocyte lineage is the first step in adipogenesis, followed by terminal differentiation. 43 In cells that have bipotential to differentiate into osteoblasts or adipocytes and in committed pre-adipocytes such as 3T3-L1 cells, MDI is a potent inducer of adipogenesis. 44 However, MDI alone is not sufficient to induce adipocyte differentiation in multipotent MSCs, 45 suggesting that some level of adipocyte commitment is necessary for MDIinduced adipogenesis. BMP4 is a member of the TGFb superfamily that promotes commitment of MSCs to an adipocyte lineage [45] [46] [47] through regulating Wnt (wingless-type Values are expressed as mean AE SE. Significance between groups was determined using a repeated measures two-way ANOVA, followed by Tukey's multiple comparisons test. For each time point, * represents a significant difference between MDI and both MDI-I and MDI-R, y represents a significant difference between MDI-I and MDI-R, z represents a significant difference between MDI and MDI-R, and § represents a significant difference between MDI and MDI-I (P < 0.05). C/EBP: CCAAT-enhancer binding protein alpha; PPAR: peroxisome proliferator-activated receptor gamma; UCMSCs: umbilical cord mesenchymal stem cells MMTV integration site family) signaling. Specifically, BMP4 induces the dissociation of Zfp423 from WISP2 46 leading to nuclear translocation of Zfp423 and increased PPAR expression. 48 Zfp423 is elevated in preadipocyte cell lines and regulates basal levels of PPAR, suggesting that it may be a marker for adipocyte commitment. 48 We observed submaximal differentiation of UCMSCs in the presence of MDI, suggesting that these cells may need some prior adipocyte commitment stimulation. However, BMP4 treatment had minimal effects on increasing the responsiveness of UCMSCs to MDI. While BMP4 stimulation increased Zfp423 and decreased WISP2 gene expression, there was very little effect of BMP4 on lipid accumulation or gene expression following differentiation. Untreated UCMSCs had a relatively high basal level of PPAR protein and small amounts of lipid accumulation, suggesting that these cells may already be primed for adipocyte commitment. It is possible that a component of the UCMSC growth media induced a preadipocyte competency, making these cells more receptive to adipocyte differentiation.
In C3H10T1/2 pluripotent stem cells, MDI-I induces PPAR expression, 31 therefore it was not surprising that in our UCMSCs, MDI-I had the greatest effects on adipocyte differentiation. However, differences between the effects of MDI-I and MDI-R on UCMSC adipogenesis were not anticipated because both indomethacin and rosiglitazone are PPAR agonists. PPAR does not work alone in regulating the adipogenic program, C/EBP also plays a significant role 49, 50 and C/EBP and PPAR work in concert to regulate terminal differentiation of adipocytes by increasing the expression of each other and of key genes regulating adipocyte functions. 24, 51 Because PPAR protein levels did not differ between groups of UCMSCs, indomethacin-or rosiglitazone-stimulated PPAR expression cannot explain the phenotypic differences observed in differentiated UCMSCs. Thus, MDI-I-induced expression of C/EBP may be driving increased differentiation of UCMSCs treated with MDI-I.
Obesity is often accompanied with hyperinsulinemia and insulin resistance of adipose, liver, and muscle tissues. Chronic insulin treatment in differentiated 3T3-L1 cells induces an insulin resistant state that is characterized by impaired PI3-kinase and MAP-kinase signaling. 52 To our knowledge, this is the first report testing the insulin responsiveness of UCMSCs differentiated into adipocytes. Although the UCMSCs showed significant activation of AKT following insulin stimulation by two weeks of differentiation, by five weeks only the cells differentiated with MDI retained insulin sensitivity. These results are surprising, especially since thiazolidinediones, such as rosiglitazone, are insulin sensitizers. Additionally, C/ EBP, which is most elevated in the MDI-I group, is essential for maintaining insulin responsiveness. 53 Increased oxidative stress, ER stress, and mitochondrial dysfunction have all been implicated as potential mechanisms underlying the insulin resistance developed from chronic insulin exposure in 3T3-L1 cells. 54 Accordingly, indomethacin has been shown to induce oxidative stress and mitochondrial dysfunction in intestinal cells. 55 suggesting a potential mechanism for reduced insulin sensitivity in MDI-I differentiated UCMSCs. Alternatively, a more recent report indicates that a certain level of reactive oxygen species (ROS) production is necessary for adipogenesis to take place 56 and perhaps part of the potency of indomethacin as a inducer of adipogenesis is through stimulating ROS production.
Besides its role in regulating glucose uptake, insulin is also responsible for regulating a number of other metabolic and mitogenic pathways. ERK1/2 is a key mediator of the mitogenic actions of insulin 57 and is important for the insulin effects on adipocyte differentiation, 58 while JNK activation can induce insulin resistance 59-61 by inhibiting insulin signaling. Interestingly, although ERK1/2 activation increased over time with adipocyte differentiation, UCMSCs did not respond to insulin by activating ERK1/ 2, suggesting that this mitogenic pathway was inactive. We observed the activation of JNK in response to insulin stimulation earlier during differentiation, however this was reversed by five weeks.
In conclusion, the present studies uncover fundamental aspects of UCMSC differentiation capacity towards the adipocytic lineage. Our findings clearly demonstrate that while all three conditions promote adipocyte differentiation, MDI-I was the most effective at inducing adipocyte differentiation. These findings are consistent with indomethacin-dependent regulation of C/EBPb and C/EBP Figure 5 Analysis of C/EBP and C/EBPb protein levels following 0, 1, and 3 days exposure to indomethacin. Protein levels of C/EBP and C/EBPb in UCMSCs treated with 60 mmol/L indomethacin for 0 (black bar), 1 (gray bar), and 3 (white bar) days were analyzed via immunoblot analysis. The graph depicts densitometric quantitation of immunoblots probed for C/EBP and C/EBPb. Values are expressed as mean AE SE. Significance between groups was determined using a repeated measures two-way ANOVA, followed by Tukey's test for multiple comparisons. For each time point, * represents a significant difference between MDI and both MDI-I and MDI-R, y represents a significant difference between MDI-I and MDI-R, z represents a significant difference between MDI and MDI-R, and § represents a significant difference between MDI and MDI-I (P < 0.05). C/EBP: CCAAT-enhancer binding protein alpha; UCMSCs: umbilical cord mesenchymal stem cells as an underlying mechanism for the potent effects of MDI-I on UCMSC adipogenesis. Importantly, the present findings also suggest that UCMSCs demonstrate minimal adipocyte differentiation in the absence of a PPAR ligand (MDI-alone), which cannot be rescued by BMP4-induced commitment. Finally, these studies reveal that ex vivo differentiated UCMSCs are insulin responsive early in differentiation but have decreased sensitivity by five weeks of differentiation. Overall, these data provide primary evidence relating to the functional capacity of ex vivo differentiated UCMSC-derived adipocytes and their adipogenic potential. 
